Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20306504 | 0.81 | ELANE (0.54) | ELANELMNAMAPTNPSR1MAPK1 | |
| SCHEMBL17938475 | 0.81 | ELANE (0.54) | ELANELMNAMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL10909324 | 0.80 | ELANE (0.46) | ELANESMN1; SMN2MAPK1 | |
| SCHEMBL364665 | 0.79 | ELANE (0.53) | ELANELMNAMAPTNPSR1MAPK1 | |
| SCHEMBL31031255 | 0.79 | ELANE (0.53) | ELANELMNAMAPTNPSR1MAPK1 | |
| SCHEMBL29607284 | 0.77 | ELANE (0.74) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL24926410 | 0.77 | ELANE (0.53) | ELANELMNAMAPTCA2SMN1; SMN2 | |
| SCHEMBL9297160 | 0.77 | MAPK1 (0.61) | LMNAMAPTTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL28030915 | 0.75 | ELANE (0.42) | ELANELMNANPSR1CA2 | |
| SCHEMBL27615323 | 0.75 | ADRB1 (0.42) | LMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | disclosed |